WAYNE, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Jefferies London Healthcare Conference, on Thursday, November 21, 2024, at 9:30 a.m. (GMT). A live audio webcast of the conference presentation will be available on the investor section of the Teleflex website at teleflex.com. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?Developed ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Sc ...

Teleflex Incorporated (TFX) posted third-quarter 2024 adjusted earnings per share (EPS) from continuing operations of $3.49, down 3.1% from the year-ago quarter’s figure. The metric topped the Zacks Consensus Estimate by 3.3%.GAAP EPS came in at $2.36 in the third quarter, down 32.4% year over year.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Following the announcement, shares of the company tumbled 14.5% yesterday, finishing the session at $201.06.TFX’s Q3 RevenuesNet revenues in ...

财务数据和关键指标变化 - 第三季度收入为764.4百万美元，同比增长2.4%，调整后按固定汇率计算增长2.2% [6] - 第三季度调整后每股收益为3.49美元，同比下降4.1% [7][29] - 调整后毛利率为60.8%，同比增长140个基点 [26] - 调整后营业利润率为27.3%，同比增长10个基点 [27] 各条业务线数据和关键指标变化 - 血管通路业务收入为180.9百万美元，同比增长6.3% [11] - 介入业务收入为149.9百万美元，同比增长11.4% [12] - 麻醉业务收入为101.1百万美元，同比增长3.4% [12] - 外科业务收入为111.7百万美元，同比下降1% [13] - 介入泌尿学业务收入为83.4百万美元，同比增长13.3% [14] - OEM收入为82.6百万美元，同比增长0.1%，表现低于预期 [14] 各个市场数据和关键指标变化 - 美洲市场收入为433.3百万美元，同比增长1.5% [8] - 欧洲、中东和非洲（EMEA）市场收入为150.2百万美元，同比增长3.9% [8] - 亚洲市场收入为98.3百万美元，同比增长5% [9] 公司战略和发展方向和行业竞争 - 公司计划继续专注于推动可持续增长，特别是在介入泌尿学和血管通路领域 [44] - 公司在美国市场的介入气球泵（IABP）业务预计将受益于竞争对手的市场退出 [19][21] - 公司将继续扩展制造能力，以满足市场需求 [21] 管理层对经营环境和未来前景的评论 - 管理层对OEM业务的表现感到失望，主要受到客户垂直整合和库存管理的影响 [47] - 管理层对Palette Life Sciences的收购表现感到满意，并提高了2024年的收入指导 [18] - 管理层预计2024年整体收入增长将受到OEM和介入泌尿学业务的压力 [34] 其他重要信息 - 公司在2024年的现金流表现强劲，预计全年现金流将超过5亿美元 [43] - 公司计划继续进行股东回报，包括股票回购和潜在的并购机会 [32][52] 问答环节所有提问和回答 问题: OEM业务的销售压力 - OEM业务的销售压力主要来自于客户的垂直整合和库存管理，预计这一影响将持续到明年上半年 [55] 问题: UroLift的市场表现 - UroLift的市场表现仍然主要集中在医生办公室，预计在2025年将结束当前的报销变化趋势 [57] 问题: IABP市场的机会 - IABP市场的机会预计将在2025年上半年持续，订单量强劲，主要来自于竞争对手的市场退出 [66][68] 问题: M&A与股票回购的平衡 - 公司在并购和股票回购之间保持平衡，计划在寻找非EPS稀释资产的同时继续进行股票回购 [51][90] 问题: Barrigel与UroLift的协同效应 - Barrigel的销售团队与UroLift的销售团队已整合，Barrigel的表现超出预期，预计将继续推动增长 [80]

For the quarter ended September 2024, Teleflex (TFX) reported revenue of $764.38 million, up 2.4% over the same period last year. EPS came in at $3.49, compared to $3.64 in the year-ago quarter.The reported revenue represents a surprise of -0.43% over the Zacks Consensus Estimate of $767.64 million. With the consensus EPS estimate being $3.38, the EPS surprise was +3.25%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine the ...

Teleflex (TFX) came out with quarterly earnings of $3.49 per share, beating the Zacks Consensus Estimate of $3.38 per share. This compares to earnings of $3.64 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.25%. A quarter ago, it was expected that this medical equipment maker would post earnings of $3.33 per share when it actually produced earnings of $3.42, delivering a surprise of 2.70%.Over the last four quarters, the co ...

Exhibit 99.1 FOR IMMEDIATE RELEASE October 31, 2024 Teleflex Reports Third Quarter Financial Results and Full Year 2024 Outlook Wayne, PA -- Teleflex Incorporated (NYSE: TFX) (the "Company") today announced financial results for the third quarter ended September 29, 2024. | --- | --- | |---------------------------------------------------------|----------------------------------------------------------------------------------------------------------------| | | | | Third quarter financial summary | | | • GAAP ...

WAYNE, Pa., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the "Company") today announced financial results for the third quarter ended September 29, 2024. Third quarter financial summary GAAP revenue of $764.4 million, up 2.4% compared to the prior year period, up 2.2% on a constant currency basis GAAP diluted EPS from continuing operations of $2.36, compared to $2.91 in the prior year period Adjusted diluted EPS from continuing operations of $3.49, compared to $3.64 in the prior year ...

WAYNE, Pa., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the first patient enrolled in the latest Barrigel™ rectal spacer randomized, controlled, single-blinded multicenter study: The PPRT Trial. Barrigel™ rectal spacer is the first and only sculptable hyaluronic acid rectal spacer designed to significantly reduce radiation that reaches the rectum during prostate radiation therapy.1-3 This new study will evaluate Barr ...